F Balieva1, J Kupfer2, L Lien3,4, U Gieler5, A Y Finlay6, L Tomás-Aragonés7, F Poot8, L Misery9,10, F Sampogna11, H van Middendorp12, J A Halvorsen13, J C Szepietowski14, A Lvov15, S E Marrón16, M S Salek17, F J Dalgard18. 1. Department of Dermatology, Stavanger University Hospital, Stavanger, Norway. 2. Institute of Medical Psychology, Justus Liebig University, Giessen, Germany. 3. Innlandet Hospital Trust, Brumundal, Norway. 4. Hedmark University College, Elverum, Norway. 5. Department of Dermatology, Justus Liebig University, Giessen, Germany. 6. Department of Dermatology, Cardiff University School of Medicine, Cardiff, U.K. 7. Department of Psychology, University of Zaragoza, Zaragoza, Spain. 8. Department of Dermatology, ULB, Hospital Erasme, Brussels, Belgium. 9. Department of Dermatology, University Hospital of Brest, Brest, France. 10. Laboratory of Neurosciences of Brest, University of Western Brittany, Brest, France. 11. Clinical Epidemiology Unit, Istituto Dermopatico dell'Immacolata, Rome, Italy. 12. Health, Medical and Neuropsychology Unit, Leiden University, Leiden, The Netherlands. 13. Department of Dermatology, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo, Norway. 14. Department of Dermatology, Wroclaw Medical University, Wroclaw, Poland. 15. Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia. 16. Department of Dermatology, Alcaniz Hospital, Alcaniz, Spain. 17. Department of Pharmacy, Pharmacology and Postgraduate Medicine, School of Life and Medical Sciences, Hatfield, U.K. 18. Department of Dermatology and Venereology, Skåne University Hospital, Lund University, S-20502, Malmö, Sweden.
Abstract
BACKGROUND: Generic instruments measuring health-related quality of life (HRQoL), like EQ5D™, enable comparison of skin diseases with healthy populations and nondermatological medical conditions, as well as calculation of utility data. OBJECTIVES: To measure HRQoL in patients with common skin diseases and healthy controls across Europe using the EQ5D. METHODS: This multicentre observational cross-sectional study was conducted in 13 European countries. Each dermatology clinic recruited at least 250 consecutive adult outpatients to complete questionnaires, including the EQ5D. RESULTS: There were 5369 participants (4010 patients and 1359 controls). Mean ± SD self-rated health state reported by patients was 69·9 ± 19·7; for controls it was 82·2 ± 15·5. When adjusted for confounding factors, including comorbidity, mean patient EQ visual analogue scores were 10·5 points lower than for controls (standardized β = -0·23). Odds ratio with 95% confidence interval for impairment in all five dimensions of EQ5D adjusted for confounders was doubled for patients compared with controls. Patients with hidradenitis suppurativa (HS), blistering conditions, leg ulcers, psoriasis and eczemas had the highest risk for reduction in HRQoL in most dimensions (2-10-fold). Data on differences of impairment by dimensions offer new insights. CONCLUSIONS: This study confirms the large impact skin conditions have on patients' well-being, differentiating between aspects of HRQoL. Patients with HS, blistering diseases, leg ulcers, infections and most chronic skin diseases reported reduced HRQoL compared with patients with chronic obstructive lung disease, diabetes mellitus, cardiovascular disease and cancers. These findings are important in the prioritization of resource allocation between medical fields and within dermatological subspecialities.
BACKGROUND: Generic instruments measuring health-related quality of life (HRQoL), like EQ5D™, enable comparison of skin diseases with healthy populations and nondermatological medical conditions, as well as calculation of utility data. OBJECTIVES: To measure HRQoL in patients with common skin diseases and healthy controls across Europe using the EQ5D. METHODS: This multicentre observational cross-sectional study was conducted in 13 European countries. Each dermatology clinic recruited at least 250 consecutive adult outpatients to complete questionnaires, including the EQ5D. RESULTS: There were 5369 participants (4010 patients and 1359 controls). Mean ± SD self-rated health state reported by patients was 69·9 ± 19·7; for controls it was 82·2 ± 15·5. When adjusted for confounding factors, including comorbidity, mean patient EQ visual analogue scores were 10·5 points lower than for controls (standardized β = -0·23). Odds ratio with 95% confidence interval for impairment in all five dimensions of EQ5D adjusted for confounders was doubled for patients compared with controls. Patients with hidradenitis suppurativa (HS), blistering conditions, leg ulcers, psoriasis and eczemas had the highest risk for reduction in HRQoL in most dimensions (2-10-fold). Data on differences of impairment by dimensions offer new insights. CONCLUSIONS: This study confirms the large impact skin conditions have on patients' well-being, differentiating between aspects of HRQoL. Patients with HS, blistering diseases, leg ulcers, infections and most chronic skin diseases reported reduced HRQoL compared with patients with chronic obstructive lung disease, diabetes mellitus, cardiovascular disease and cancers. These findings are important in the prioritization of resource allocation between medical fields and within dermatological subspecialities.
Authors: Zarine S Patel; Lauren K Hoffman; Dawn C Buse; Amy S Grinberg; Ladan Afifi; Steven R Cohen; Michelle A Lowes; Elizabeth K Seng Journal: Curr Pain Headache Rep Date: 2017-11-01
Authors: Mirkka J Hirvonen; Rafael Pasternack; Tiina Lipitsä; Armi Vihervaara; Rauno Harvima; Martta Ranta; Harri Sintonen; Laura Huilaja Journal: Skin Appendage Disord Date: 2021-12-27
Authors: Kevin T Savage; Vinita Singh; Zarine S Patel; Christine A Yannuzzi; Anne Marie McKenzie-Brown; Michelle A Lowes; Lauren A V Orenstein Journal: J Am Acad Dermatol Date: 2020-09-17 Impact factor: 15.487